Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

DIASYS DIAGNOSTIC SYSTEMS

Develops, manufactures, and distributes diagnostic systems for clinical chemistry and immunoturbidimetry. Supplies hi... read more Featured Products: More products

Download Mobile App





DiaSys Presents New Assays and Clinical Chemistry Analyzers at MEDICA 2022

By LabMedica International staff writers
Posted on 14 Nov 2022

DiaSys Diagnostic Systems GmbH (Holzheim, Germany) is presenting its new assays to determine HDL and LDL-cholesterol, alongside the respons®940, the new member of the company’s family of clinical chemistry analyzers, at MEDICA 2022. More...

The MEDICA 2022 Trade Fair is being held in Düsseldorf, Germany from 14-17th November. More than 5,000 exhibitors from 70 countries are presenting their newest products and ideas at MEDICA which draws 120,000 trade visitors from over 170 countries every year.

At this year’s edition of MEDICA, DiaSys is exhibiting respons®910, a compact and fully-automated bench top clinical chemistry analyzer designed for maximum efficiency. Its high on-board capacity of 30 different methods in mono- or twin-containers and 30 sample positions offer the necessary flexibility for everyday use. The integrated STAT port allows easy loading of emergency samples at any time. The wide range of high-quality clinical chemistry and immunoturbidimetric tests manufactured by DiaSys rounds off the respons®910 system.

DiaSys is also presenting the HDL-c direct FS and LDL-c direct FS, its two innovative new reagents added to its cardiovascular risk assessment portfolio. Both are homogenous assays for direct determination and offer long calibration and onboard stability of up to four months. Combined with wide measuring ranges and good precision at clinical cut-off points, DiaSys assays HDL-c direct FS and LDL-c direct FS are of high value for clinical-chemistry laboratories.

Another highlight at the company’s booth at MEDICA 2022 is the presentation of Procalcitonin FS, an innovative, immunoturbidimetric assay to determine Procalcitonin that offers an excellent alternative to established methods. Procalcitonin FS offers a reliable alternative, when time matters in sepsis management. The fluid-stable, particle enhanced immunoturbidimetric assay is characterized by a good precision at clinical cut-off levels and high prozone security. Procalcitonin FS has good onboard and calibration stability and shows high tolerance to endogenous interferents and common therapeutics used in sepsis management. Additionally, the assay shows good concordance to established methods. Procalcitonin FS, dedicated kits are available for the DiaSys respons® systems and BioMajesty® JCA-BM6010/C.

Related Links:
DiaSys Diagnostic Systems


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.